Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
Raveen Rathnasinghe, Sonia Jangra, Anastasija Čupić, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 970
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Peter Halfmann, Shun Iida, Kiyoko Iwatsuki‐Horimoto, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 687-692
Open Access | Times Cited: 589
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, et al.
The Lancet Microbe (2021) Vol. 2, Iss. 7, pp. e283-e284
Open Access | Times Cited: 414
After the pandemic: perspectives on the future trajectory of COVID-19
Amalio Telenti, Ann M. Arvin, Lawrence Corey, et al.
Nature (2021) Vol. 596, Iss. 7873, pp. 495-504
Open Access | Times Cited: 388
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature (2021) Vol. 596, Iss. 7870, pp. 103-108
Open Access | Times Cited: 251
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 516-521.e3
Open Access | Times Cited: 235
Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
Ruoke Wang, Qi Zhang, Jiwan Ge, et al.
Immunity (2021) Vol. 54, Iss. 7, pp. 1611-1621.e5
Open Access | Times Cited: 227
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 211
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
Tia A. Tummino, Veronica V. Rezelj, Benoit Fischer, et al.
Science (2021) Vol. 373, Iss. 6554, pp. 541-547
Open Access | Times Cited: 185
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
Alba Escalera, Ana S. González-Reiche, Sadaf Aslam, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 3, pp. 373-387.e7
Open Access | Times Cited: 174
Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
Lianlian Bian, Fan Gao, Jialu Zhang, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 4, pp. 365-373
Open Access | Times Cited: 168
Emerging SARS-CoV-2 variants expand species tropism to murines
Huiping Shuai, Jasper Fuk‐Woo Chan, Terrence Tsz‐Tai Yuen, et al.
EBioMedicine (2021) Vol. 73, pp. 103643-103643
Open Access | Times Cited: 168
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Dami A. Collier, Anna De Marco, Isabella A. T. M. Ferreira, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 166
SARS-CoV-2 one year on: evidence for ongoing viral adaptation
Thomas P. Peacock, Rebekah Penrice-Randal, Julian A. Hiscox, et al.
Journal of General Virology (2021) Vol. 102, Iss. 4
Open Access | Times Cited: 166
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Daniele Focosi, Fabrizio Maggi
Reviews in Medical Virology (2021) Vol. 31, Iss. 6
Open Access | Times Cited: 161
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 152
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera
Sonia Jangra, Chengjin Ye, Raveen Rathnasinghe, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 143
Variants with the N501Y mutation extend SARS-CoV-2 host range to mice, with contact transmission
Xavier Montagutelli, Matthieu Prot, Laurine Levillayer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 120
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1303-1303
Open Access | Times Cited: 120
The Spike of Concern—The Novel Variants of SARS-CoV-2
Anna Winger, Thomas Caspari
Viruses (2021) Vol. 13, Iss. 6, pp. 1002-1002
Open Access | Times Cited: 110
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Baoling Ying, Suzanne M. Scheaffer, Bradley Whitener, et al.
Cell (2022) Vol. 185, Iss. 9, pp. 1572-1587.e11
Open Access | Times Cited: 89
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Ahmed I. Abulsoud, Hussein M. El‐Husseiny, Ahmed A. El-Husseiny, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 113977-113977
Open Access | Times Cited: 88
Advances and gaps in SARS-CoV-2 infection models
César Muñoz‐Fontela, Lina Widerspick, Randy A. Albrecht, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 1, pp. e1010161-e1010161
Open Access | Times Cited: 77
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Baoling Ying, Bradley Whitener, Laura A. VanBlargan, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 630
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top